Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.35 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662278 | 0.75 | HTR1A (0.68) | HTR1AHTR7CYP1A2KDM4ELMNA | |
| SCHEMBL12794542 | 0.75 | CCR1 (0.51) | HTR1AHTR7GRM5CYP1A2KDM4E | |
| Hydrazine SCHEMBL8524800 | 0.74 | KDM4E (0.52) | ULK1CDK7CDK5PRKCECAMK2G | |
| SCHEMBL30031 | 0.74 | KDM4E (0.56) | IDO1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL4844394 | 0.72 | CCR1 (0.52) | GRM5CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL4755586 | 0.72 | KDM1A (0.48) | IDO1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL7553180 | 0.72 | CCR1 (0.51) | GRM5CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL2138825 | 0.72 | KDM4E (0.42) | GRM5IDO1CYP1A2KDM4ELMNA | |
| SCHEMBL16241819 | 0.72 | KDM4E (0.54) | IDO1CYP1A2KDM4ELMNAPOLB | |
| SCHEMBL15436287 | 0.72 | KDM4E (0.54) | IDO1CYP1A2KDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | claimed |
| EP-3129065-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Invictus Oncology Pvt. Ltd. (IN) | 2017-02-15 | — | — | EP | claimed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | claimed |
| WO-2015148126-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-01 | — | — | WO | claimed |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Akamara Therapeutics, Inc. (US) | 2020-06-25 | — | — | US | disclosed |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | Akamara Therapeutics, Inc. (US) | 2020-01-14 | — | — | US | disclosed |
| EP-3129065-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | Invictus Oncology Pvt. Ltd. (IN) | 2017-02-15 | — | — | EP | disclosed |
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2017-01-19 | — | — | US | disclosed |
| WO-2015148126-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | INVICTUS ONCOLOGY PVT. LTD. (IN) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014528-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, ADAM8, TIE1 | HTR1A 3029/4885HTR7 2227/4885GRM5 1897/4885 |
| US-11701429-B2 | Targeted drug delivery through affinity based linkers | ABCG2, FCGR2A, ABCB1 | HTR1A 3366/4885HTR7 1722/4885GRM5 2062/4885 |
| US-20200199249-A1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | ABCG2, FCGR2A, ABCB1 | HTR1A 3366/4885HTR7 1722/4885GRM5 2062/4885 |
| US-10533059-B2 | Targeted drug delivery through affinity based linkers | ABCG2, ADAM8, TIE1 | HTR1A 3029/4885HTR7 2227/4885GRM5 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.